<DOC>
	<DOCNO>NCT02444884</DOCNO>
	<brief_summary>RATIONALE : MLN8237 may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase I/II trial study side effect best dose MLN8237 see well work treat young patient relapsed refractory solid tumor</brief_summary>
	<brief_title>MLN8237 Treat Children With Relapsed/Refractory Solid Tumors</brief_title>
	<detailed_description>1.1 Primary Aims 1.1.1 To estimate maximum tolerate dose ( MTD ) recommend Phase II dose MLN8237 administer orally daily 7 day every 21 day child refractory solid tumor . 1.1.2 To estimate maximum tolerate dose ( MTD ) recommend Phase II dose MLN8237 administer orally twice daily 7 day every 21 day child refractory solid tumor . 1.1.3 To define describe toxicity MLN8237 administer schedule . 1.1.4 To characterize pharmacokinetics MLN8237 child refractory cancer . 1.2 Secondary Aims 1.2.1 To preliminarily define antitumor activity MLN8237 within confines Phase I study . 1.2.2 To obtain initial Phase II efficacy data anti-tumor activity MLN8237 child relapsed-refractory neuroblastoma use daily dose schedule . 1.2.3 To explore relationship polymorphic variation UDPglucuronyltransferase gene UGT1A1 exposure MLN8237 . 1.2.4 To assess two common polymorphic variant Aurora A kinase gene ( Phe31Ile Val57Ile ) think potentially influence tumorigenesis . 1.2.5 To preliminarily examine relationsh</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>Diagnosis : Patients must histologic verification malignancy original diagnosis relapse except patient intrinsic brain stem tumor , optic pathway glioma , patient pineal tumor elevation CSF serum tumor marker include alphafetaprotein betaHCG . Performance Level : Karnofsky &gt; /= 50 % patient &gt; 16 year age Lansky &gt; /= 50 patient &lt; /=16 year age Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study Adequate Bone Marrow Function Defined : . For patient solid tumor : Peripheral absolute neutrophil count ( ANC ) &gt; /= 1000/microLiter Platelet count &gt; /= 100,000/microLiter ( transfusion independent , define receive platelet transfusion within 7 day period prior enrollment ) Hemoglobin &gt; /= 8.0 g/dL ( may receive RBC transfusion ) Creatinine clearance radioisotope GFR &gt; /= 70ml/min/1.73 m2 Bilirubin ( sum conjugate + unconjugated ) &lt; /= 1.5 x upper limit normal ( ULN ) age , SGPT ( ALT ) &lt; /= 5.0 x ULN age ( â‰¤ 225 U/L ) . For purpose study , ULN SGPT 45 U/L . Serum albumin &gt; /= 2 g/dL . Pregnant breastfeed woman enter study Growth factor support platelet white cell number function must administer within 7 day prior enrollment . Patients receive corticosteroid stable decrease dose corticosteroid prior 7 day eligible . Patients currently receive another investigational drug eligible . Patients currently receive anticancer agent , digoxin , cyclosporine , tacrolimus sirolimus , use daily benzodiazepine eligible Patients uncontrolled infection eligible .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>